title: Bioengineering heterodimeric cytokines: turning promiscuous proteins into therapeutic agents.
abstract: The interleukin 12 (IL-12) family comprises a group of heterodimeric cytokines that can cope with a great variety of immune conditions as the microenvironment demands. By sharing cytokine and receptor subunits, IL-12 (comprised of p40/p35 subunits), IL-23 (p40/p19), IL-27 (p28/EBI3), and IL-35 (p35/EBI3) represent, as a whole, a highly versatile system participating in controlling the continuum from inflammation to tolerance. Promiscuity, a peculiar feature of those cytokines, is a powerful and economic means of producing individual factors with distinct activities via different combinations of a single set of subunits. Whereas IL-12 and IL-23 have a clearly dominant immunostimulatory functional profile and IL-35 is a potent immunosuppressive agent, IL-27 can exert both adjuvant and regulatory effects, depending on the cytokine milieu. Promiscuity itself, however, may significantly hamper the therapeutic use of heterodimeric cytokines. The subunits of a recombinant cytokine, when administered in its native form, will rapidly dissociate in vivo and reassociate with alternative partners, thus generating different heterodimeric or even homodimeric molecules (i.e., p40/p40) with unwanted effects. As in other areas, bioengineering has provided a formidable tool to overcome the constraints associated with the potential use of IL-12 family cytokines. The generation of several gene constructs expressing IL-12, IL-23, IL-27, IL-35, or even the homodimer p40/p40, in their monomerized, single-chain form has allowed us to unveil the efficacy of those molecules in several experimental settings, including neoplasia, viral infection, chronic inflammation, allergy and autoimmunity. Although work is still needed to obtain an overall picture of therapeutic vs. adverse effects of individual molecules before any use in humans, the new frontiers of bioengineering are now driving the production of completely new combinations of cytokine subunits that may further extend the potential clinical use of such eclectic proteins.
authors.affiliation: a Department of Experimental Medicine and Biochemical Sciences , University of Perugia , Italy.
authors.forename: Maria Laura
authors.initials: ML
authors.lastname: Belladonna
authors.forename: Ursula
authors.initials: U
authors.lastname: Grohmann
mesh_terms: D000595:Amino Acid Sequence; D057005:Bioengineering; D016207:Cytokines / Q000737:chemistry / Q000235:genetics* / Q000627:therapeutic use; D019281:Dimerization; D006801:Humans; D018664:Interleukin-12 / Q000737:chemistry / Q000235:genetics; D053759:Interleukin-23 / Q000737:chemistry / Q000235:genetics / Q000627:therapeutic use; D064094:Interleukin-27 / Q000737:chemistry / Q000235:genetics / Q000627:therapeutic use; D007378:Interleukins / Q000737:chemistry / Q000235:genetics / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000235:genetics* / Q000627:therapeutic use*
chemical_list: D016207:Cytokines; D053759:Interleukin-23; D064094:Interleukin-27; D007378:Interleukins; D011993:Recombinant Fusion Proteins; C532417:interleukin-35, human; D018664:Interleukin-12